skip to main content

HIF-PHI Advantages Over ESA — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateChronic Kidney DiseaseHIF-PHI Advantages Over ESAESENeph

A 60-year-old man with CKD G5D on HD has been receiving Darbepoetin 40 mcg every 2 weeks. His Hb has been stable at 108 g/L for 6 months. His nephrologist considers switching to a HIF-PHI (Roxadustat). What potential advantage does an oral HIF-PHI offer over injectable ESA?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Oral administration improves convenience and eliminates injection burden; HIF-PHIs also enhance endogenous iron utilisation (reducing IV iron requirements), stimulate endogenous EPO production more physiologically, and may benefit patients with ESA hyporesponsiveness from inflammation – though long-term safety data is still accumulating

HIF-PHIs (Roxadustat, Daprodustat, Vadadustat) offer several potential advantages: (1) oral administration (convenience, no injections); (2) stimulate endogenous EPO production (more physiological than supraphysiological exogenous EPO); (3) improve iron metabolism (suppress hepcidin, increase iron absorption and mobilisation – potentially reducing IV iron needs); (4) may benefit patients with ESA hyporesponsiveness from inflammation (HIF pathway circumvents some inflammatory resistance). Concerns include: potential VEGF-mediated effects, thrombosis risk, tumour growth promotion, and hepatotoxicity. NICE TA920 (2023) approved Roxadustat for CKD anaemia.

Reference: KDIGO 2025 – Anemia; NICE TA920 – Roxadustat; Dhillon 2019